Abstract
Clinical and non-clinical studies have shown that intramuscular ultra-high dose methylcobalamin is potentially effective against amyotrophic lateral sclerosis (ALS). Post hoc analyses in a previous phase 2/3 clinical trial showed that methylcobalamin prolonged survival time and arrested functional decline compared to placebo in patients registered within 12 months of ALS onset. The objective of the next trial: The Japanese Early Stage Trial of High Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS), was to reconfirm the efficacy and safety of ultra-high dose methylcobalamin for ALS patients in their early stages. (NCT03548311).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
